Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Lymphatics
Sections
Radiation Oncology
share announcement

Radiation Oncology

A topical collection in Lymphatics (ISSN 2813-3307).

Viewed by 7662

Editors

Prof. Dr. Bouthaina S. Dabaja

E-Mail Website
Collection Editor
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: radiation oncology; hematology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Andrea K. Ng

E-Mail Website
Collection Editor
Department of Medicine, Harvard Medical School, Boston, MA, USA
Interests: Hodgkin's lymphoma; non-Hodgkin's lymphoma; radiation oncology
Dr. Paolo Strati

E-Mail Website
Collection Editor
Department of Lymphoma and Myeloma & Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: follicular lymphoma; marginal zone lymphoma; diffuse large B-cell lymphoma; immunotherapy; cellular therapy
Special Issues, Collections and Topics in MDPI journals
Dr. Michael T. Spiotto

E-Mail Website
Collection Editor
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: radiation oncology
Prof. Dr. Hans Theodor Eich

E-Mail Website
Collection Editor
Department of Radiation Oncology, University Hospital of Muenster, Muenster, Germany
Interests: radiation therapy; lymphoma
Special Issues, Collections and Topics in MDPI journals
Dr. Nicholas J. Short

E-Mail Website
Collection Editor
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: acute lymphoblastic leukemia; acute myeloid leukemia; measurable residual disease
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. N. George Mikhaeel

E-Mail Website
Collection Editor
Department of Clinical Oncology, Guy's & St Thomas' NHS Foundation Trust, London, UK
Interests: lymphoma; radiotherapy for haematological malignancies; advanced radiotherapy techniques; imaging in lymphoma

Topical Collection Information

Dear Colleagues, 

The aim of this Collection of the journal Lymphatics is to enable rapid publications of scientific contributions and discoveries in the field of radiation oncology in reference to hematological malignancies.

Over the past five decades, the role and application of radiation therapy have dramatically changed, leading to 1) a reduction in the radiation fields and doses to mitigate the long-term toxicities seen when using outdated radiation; 2) the introduction of new indications for radiation treatment, 3) and most importantly, the employment of the radiation ability to produce immunogenic cell death, facilitating its introduction into the environment of immunotherapy and cellular therapy.

Topics include, but are not limited to:

  • Radiation techniques
  • Motion control management
  • Applications of radiation fields and dose
  • Mitigating radiation toxicity
  • Radiation as consolidation post systemic therapy
  • Combined modality with radiation and chemotherapy
  • Combined radiation and immunotherapy
  • Radiation as a conditioning prior to stem cell transplant
  • Radiation as bridging in the cellular therapy environment
  • Novel indications for radiation use
  • Mechanisms of radiation induced immunogenicity
  • Radiation in the palliative setting

We also welcome reviews on these subjects, particularly those that challenge existing concepts.

Prof. Dr. Bouthaina S. Dabaja
Prof. Dr. Andrea K. Ng
Dr. Paolo Strati
Dr. Michael T. Spiotto
Prof. Dr. Hans Theodor Eich
Dr. Nicholas J. Short
Prof. Dr. N. George Mikhaeel
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Lymphatics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (4 papers)

Download All Papers

2024

Jump to: 2023

9 pages, 33218 KiB  
Brief Report
Motion Management: The Road Map to Accurate Radiation Treatment Delivery
by Bouthaina Dabaja, Susan Wu and Nicholas J. Short
Lymphatics 2024, 2(1), 1-9; https://doi.org/10.3390/lymphatics2010001 - 1 Jan 2024
Viewed by 1291
Abstract
Radiation therapy is a key contributor to positive outcomes in hematological malignancies. However, this is contingent on minimizing the exposure of critical normal organs. The introduction of computed tomography (CT) for radiation treatment planning and the development of sophisticated dose calculation algorithms has [...] Read more.
Radiation therapy is a key contributor to positive outcomes in hematological malignancies. However, this is contingent on minimizing the exposure of critical normal organs. The introduction of computed tomography (CT) for radiation treatment planning and the development of sophisticated dose calculation algorithms has transformed the radiation therapy field and made it possible to transition from conventional involved-field radiation to modern involved-site radiation therapy. Thanks to rapid advances in drug discovery, treatment strategies for many hematological malignancies have evolved to incorporate targeted and cellular therapies, in some cases even allowing the replacement of chemotherapy. As a result, new opportunities have been created for radiation to address relapses after more lines of therapy, identify disease-involving sanctuary sites, and bridge to the subsequent therapy. When considering radiation in patients receiving novel therapies, who may also be more heavily pretreated, respecting the critical and normal structures at all costs is imperative. In this document, we will describe modern techniques used to deliver state-of-the-art radiation therapy and practical considerations to ensure the accurate treatment of the target while avoiding normal organs at risk. Full article
►▼ Show Figures

Graphical abstract

2023

Jump to: 2024

14 pages, 1510 KiB  
Review
Incorporating Immunotherapy with Radiotherapy for Lymphomas
by Paolo Strati and Michael T. Spiotto
Lymphatics 2023, 1(3), 273-286; https://doi.org/10.3390/lymphatics1030018 - 7 Dec 2023
Viewed by 1519
Abstract
Radiotherapy and/or chemotherapy have been used for nearly 100 years to treat lymphoma. Recently, immunotherapy has been incorporated into the treatment of lymphomas. Here, we will review both the role of immunotherapy in lymphoma as well as the feasibility of incorporating immunotherapies with [...] Read more.
Radiotherapy and/or chemotherapy have been used for nearly 100 years to treat lymphoma. Recently, immunotherapy has been incorporated into the treatment of lymphomas. Here, we will review both the role of immunotherapy in lymphoma as well as the feasibility of incorporating immunotherapies with conventional lymphoma treatments, especially radiotherapy. Immunotherapy agents include checkpoint inhibitors that target the PD-1/PD-L1 axis, CTLA-4, or CD47. In addition, other immunotherapy agents such as bi-specific antibodies and CD19 CAR-T cell therapy are being implemented in various non-Hodgkin’s lymphomas. Extrapolating from observations in other disease sites and incorporating immunotherapy with conventional treatments of lymphoma, including radiotherapy, may have opposing effects. Radiotherapy may stimulate anti-tumor immune responses that synergize with immunotherapies. In contrast, radiotherapy, as well as chemotherapy, may also induce local and systemic immune dysfunction which reduces the efficacy of immunotherapies. With newer radiation treatment techniques and limited radiation fields, it is likely that the efficacy of immunotherapy can be maintained when included with conventional treatments. Therefore, there remains an unmet need to better understand the role of immunotherapy alone and in combination with current treatments in lymphoma patients. Full article
►▼ Show Figures

Figure 1

11 pages, 918 KiB  
Perspective
Evolution of Radiation Fields from Involved Field to Involved Site—A Summary of the Current Guidelines by the International Lymphoma Radiation Oncology Group
by Hans Theodor Eich, Niklas Benedikt Pepper and Michael Oertel
Lymphatics 2023, 1(3), 262-272; https://doi.org/10.3390/lymphatics1030017 - 8 Nov 2023
Viewed by 2154
Abstract
Radiation therapy has been proven to be highly effective in the treatment of lymphoma. With increasing rates of long-term survival, the reduction in toxicity has gained importance. The evolving understanding of the diseases’ biology, as well as technical and conceptual advances, allows for [...] Read more.
Radiation therapy has been proven to be highly effective in the treatment of lymphoma. With increasing rates of long-term survival, the reduction in toxicity has gained importance. The evolving understanding of the diseases’ biology, as well as technical and conceptual advances, allows for a precise and individualized application of irradiation. Smaller treatment fields and safety margins make it possible to spare healthy neighbouring tissue (organs at risk). The International Lymphoma Radiation Oncology Group (ILROG) has developed several guidelines to optimize radiotherapy treatment in lymphoma patients. Since its introduction in 2013, involved site radiotherapy (ISRT) has been adopted as the standard of care in most treatment regimens in adult lymphoma. This article serves as a summary of the current ILROG guidelines, also considering contemporary developments and possible future directions. Full article
►▼ Show Figures

Figure 1

10 pages, 1421 KiB  
Article
FDG PET/CT as a Tool for Early Detection of Bleomycin-Induced Pulmonary Toxicity
by Hira Shaikh, Zulfa Omer, Roman A. Jandarov, Morgan P. McBee, Jennifer Scheler, Bruce Mahoney and Tahir Latif
Lymphatics 2023, 1(1), 45-54; https://doi.org/10.3390/lymphatics1010006 - 7 Jun 2023
Viewed by 1861
Abstract
Bleomycin-induced pulmonary toxicity (BPT) is a serious and potentially fatal complication of bleomycin, a key component of Hodgkin lymphoma (HL) treatment. Before ours, only one published study evaluated the predictability of 18F-FDG-PET/CT for the early diagnosis of BPT. In this retrospective cohort study, [...] Read more.
Bleomycin-induced pulmonary toxicity (BPT) is a serious and potentially fatal complication of bleomycin, a key component of Hodgkin lymphoma (HL) treatment. Before ours, only one published study evaluated the predictability of 18F-FDG-PET/CT for the early diagnosis of BPT. In this retrospective cohort study, 18F-FDG-PET/CT scans of adult HL patients treated with bleomycin at an urban academic center over five years were assessed by radiologists blinded to the clinical information, and scans were correlated with clinical BPT. We found 11 HL patients with 54 interim or end-of-treatment 18F-FDG-PET/CT scans who had received bleomycin. Five of the eleven (5/11, 45%) patients had radiographic changes in PET/CT and developed clinical BPT. Patients with clinical BPT had higher FDG uptake in lungs compared to those who did not (SUVmax mean 2.66 (CI 1.8–3.7) vs. 0.86 (CI 0.4–1.9), Mann–Whitney U test, p < 0.05). In a separate cohort analysis, we compared HL patients with clinical BPT (9/25, 36%) and without clinical BPT (16/25, 64%) to assess potential risk factors. Low hemoglobin (p = 0.037) and high ESR values (p = 0.0289) were associated with clinical BPT. Furthermore, gender, stage, histology, prior lung radiation, G-CSF, or steroids did not significantly confer a higher risk of BPT. 18F-FDG-PET/CT imaging, which is routinely used to assess treatment response in HL, is useful for early detection of BPT, which can have high mortality and morbidity. Full article
►▼ Show Figures

Figure 1

Back to TopTop